Hematologic cancers account for 9.5% of new cancer cases diagnosed in the United States each year.1 The many stages of hematopoietic differentiation provide multiple opportunities for mutations that lead to distinct tumor subtypes.2 For this reason, accurate characterization of malignant cells is critical to understanding disease etiology and how cancer subtypes potentially relate to therapeutic options.
Among the broad spectrum of NGS methods, targeted sequencing offers easy and cost-effective entry into researching cancer genomics. Targeted sequencing focuses only on genes related to hematological cancer, generating a smaller, more manageable data set. Many samples can be pooled together and sequenced simultaneously, simplifying lab validation procedures and significantly increasing sample throughput.
Hematologic cancer profiling using NGS follows a simple workflow that can be easily scaled to hundreds of samples. Clinical research labs can go from DNA to report in approximately 40 hours. This workflow uses a single instrument, minimizing laboratory validation steps and integrating seamlessly into the lab setting.
Dr. Benedict Yan and his team of researchers focus on hematologic cancers, specifically acute myeloid leukemia (AML). Using NGS, they identified novel cancer biomarkers that Sanger sequencing missed. Learn why Dr. Yan believes that NGS could streamline AML diagnosis in the future.Read Case Study
Illumina products empower clinical cancer research labs to use the most current technologies to find accurate answers while seamlessly integrating NGS into the lab. Expert-defined panels containing relevant genes enable rapid analysis of myeloid and lymphoid malignancies.
Illumina sequencers deliver industry-leading accuracy, generating ~ 90% of the world’s sequencing data.* Efficient reporting capabilities enable researchers to annotate, classify, and communicate significant findings in a standard format that facilitates data analyses and trending.
Click on the below to view products for each workflow step.
Expert-defined panel targeting oncogenic exons and tumor suppressor genes for myeloid malignancies.TruSight Oncology UMI Reagents
The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.TruSight RNA Pan-Cancer
Targeting 1385 cancer-associated genes for gene expression, variant and fusion detection in all cancer research sample types including FFPE.
A gene fusion detection panel targeting fusion associated genes in many cancer types with the ability to detect known and novel fusion gene partners.AmpliSeq for Illumina Sequencing Solution
A highly multiplexed polymerase chain reaction (PCR)-based workflow for use with targets ranging from a few to hundreds of genes in a single run.
Small and affordable benchtop sequencer for reliable low-throughput targeted sequencing of hematological cancers.MiSeq System
Desktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.
Easy-to-use software for analysis and variant calling on the MiSeq System.VariantStudio Software
A powerful analysis and reporting tool that provides biological insight into genomic variant data.